These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 15388420)

  • 41. Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1.
    Pirrone V; Passic S; Wigdahl B; Krebs FC
    Virol J; 2012 Jan; 9():33. PubMed ID: 22281044
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro anti-HIV-1 activities of kaempferol and kaempferol-7-O-glucoside isolated from Securigera securidaca.
    Behbahani M; Sayedipour S; Pourazar A; Shanehsazzadeh M
    Res Pharm Sci; 2014; 9(6):463-9. PubMed ID: 26339261
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Approved HIV reverse transcriptase inhibitors in the past decade.
    Li G; Wang Y; De Clercq E
    Acta Pharm Sin B; 2022 Apr; 12(4):1567-1590. PubMed ID: 35847492
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nanoparticle Encapsulation for Antiretroviral Pre-Exposure Prophylaxis.
    Khandalavala K; Mandal S; Pham R; Destache CJ; Shibata A
    J Nanotechnol Mater Sci; 2017; 4(2):53-61. PubMed ID: 29881781
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The development and validation of an UHPLC-MS/MS method for the rapid quantification of the antiretroviral agent dapivirine in human plasma.
    Seserko LA; Emory JF; Hendrix CW; Marzinke MA
    Bioanalysis; 2013 Nov; 5(22):2771-83. PubMed ID: 24256358
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine.
    das Neves J; Michiels J; Ariën KK; Vanham G; Amiji M; Bahia MF; Sarmento B
    Pharm Res; 2012 Jun; 29(6):1468-84. PubMed ID: 22072053
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Persistent interactions between biguanide-based compound NB325 and CXCR4 result in prolonged inhibition of human immunodeficiency virus type 1 infection.
    Thakkar N; Pirrone V; Passic S; Keogan S; Zhu W; Kholodovych V; Welsh W; Rando R; Labib M; Wigdahl B; Krebs FC
    Antimicrob Agents Chemother; 2010 May; 54(5):1965-72. PubMed ID: 20231400
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Tian X; Qin B; Lu H; Lai W; Jiang S; Lee KH; Chen CH; Xie L
    Bioorg Med Chem Lett; 2009 Sep; 19(18):5482-5. PubMed ID: 19666220
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vaginal microbicides and the prevention of HIV transmission.
    Cutler B; Justman J
    Lancet Infect Dis; 2008 Nov; 8(11):685-97. PubMed ID: 18992405
    [TBL] [Abstract][Full Text] [Related]  

  • 50. 2D and 3D QSAR studies of diarylpyrimidine HIV-1 reverse transcriptase inhibitors.
    Rebehmed J; Barbault F; Teixeira C; Maurel F
    J Comput Aided Mol Des; 2008 Nov; 22(11):831-41. PubMed ID: 18506577
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Human immunodeficiency virus type 1 (HIV-1) integration: a potential target for microbicides to prevent cell-free or cell-associated HIV-1 infection.
    Terrazas-Aranda K; Van Herrewege Y; Hazuda D; Lewi P; Costi R; Di Santo R; Cara A; Vanham G
    Antimicrob Agents Chemother; 2008 Jul; 52(7):2544-54. PubMed ID: 18474579
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1.
    Hossain MM; Parniak MA
    J Virol; 2006 May; 80(9):4440-6. PubMed ID: 16611904
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides.
    Van Herrewege Y; Michiels J; Van Roey J; Fransen K; Kestens L; Balzarini J; Lewi P; Vanham G; Janssen P
    Antimicrob Agents Chemother; 2004 Jan; 48(1):337-9. PubMed ID: 14693562
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel diarylpyrimidines and diaryltriazines as potent HIV-1 NNRTIs with dramatically improved solubility: a patent evaluation of US20140378443A1.
    Huang B; Kang D; Yang J; Zhan P; Liu X
    Expert Opin Ther Pat; 2016; 26(2):281-9. PubMed ID: 26559996
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides.
    Van Herrewege Y; Vanham G; Michiels J; Fransen K; Kestens L; Andries K; Janssen P; Lewi P
    Antimicrob Agents Chemother; 2004 Oct; 48(10):3684-9. PubMed ID: 15388420
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activity of reverse transcriptase inhibitors in monocyte-derived dendritic cells: a possible in vitro model for postexposure prophylaxis of sexual HIV transmission.
    Van Herrewege Y; Penne L; Vereecken C; Fransen K; van der Groen G; Kestens L; Balzarini J; Vanham G
    AIDS Res Hum Retroviruses; 2002 Oct; 18(15):1091-102. PubMed ID: 12396448
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pre-incubation of cell-free HIV-1 group M isolates with non-nucleoside reverse transcriptase inhibitors blocks subsequent viral replication in co-cultures of dendritic cells and T cells.
    Njai HF; Lewi PJ; Janssen CG; Garcia S; Fransen K; Kestens L; Vanham G; Janssen PA
    Antivir Ther; 2005; 10(2):255-62. PubMed ID: 15865220
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.